Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Latigo BiotherapeuticsLTGO +1.70%8 EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus rates LTGO with a GF Score™ of 8/100. Among 942 Biotechnology companies, Latigo Biotherapeutics ranks worse than 106157.01% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Latigo Biotherapeutics EBITDA Margin % Related Terms
Latigo Biotherapeutics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Latigo Biotherapeutics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Latigo Biotherapeutics EBITDA Margin % Chart
Latigo Biotherapeutics Annual Data
Trend
Dec24
Dec25
EBITDA Margin %
0.00
0.00
Latigo Biotherapeutics Semi-Annual Data
Dec24
Dec25
EBITDA Margin %
0.00
0.00
LTGO vs : EBITDA Margin % Comparison
For the Biotechnology subindustry, Latigo Biotherapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Latigo Biotherapeutics EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Latigo Biotherapeutics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Latigo Biotherapeutics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Latigo Biotherapeutics (LTGO) has a EBITDA Margin % of 0.00% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Latigo Biotherapeutics and its competitors. According to the industry distribution chart, Latigo Biotherapeutics ranks #999999 out of 942 companies in the Biotechnology industry.
Is Latigo Biotherapeutics' EBITDA Margin % too high?
Latigo Biotherapeutics' current EBITDA Margin % is 0.00%. Based on the distribution chart, Latigo Biotherapeutics ranks #999999 out of 942 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Latigo Biotherapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Latigo Biotherapeutics' EBITDA Margin % compare to ?
According to the Biotechnology industry distribution chart, Latigo Biotherapeutics ranks #999999 out of 942 companies for EBITDA Margin %. This places Latigo Biotherapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Latigo Biotherapeutics and its competitors. Latigo Biotherapeutics's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Latigo Biotherapeutics stock overvalued right now?
Latigo Biotherapeutics (LTGO) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Latigo Biotherapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Latigo Biotherapeutics (LTGO), the current EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.
8GF Score
Get the complete analysis for LTGO
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTGO has been successfully added to your 
